Benitec Limited is a leading international biotechnology company listed on the Australian Stock Exchange (ASX:BLT) . Benitec is one of the pioneers of RNA interference (RNAi) technology, which can be used to precisely destroy RNA viruses and silence the expression of defective genes. Benitec's core patents and licenses provide key technologies to trigger RNAi in human cells and in live animals. Benitec holds exclusive worldwide rights for development and commercialization for all therapeutic human applications.
The corporate goal of Benitec is to develop RNAi-based therapeutics for serious diseases such as infectious diseases, cancers and autoimmune disorders through co-investment and out licensing. Benitec's RNA-based HIV therapeutic, co-developed with the City of Hope in Duarte, California, has entered human clinical trials.
Benitec derives revenues from out-licensing its proprietary DNA-directed RNAi (ddRNAi) technology to life sciences companies in various fields. The Company's proprietary ddRNAi technology provides unique capability and significant competitive advantages for:
